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op vroegtijdige overlijden van mensen in de algemene populatie gekwantificeerd. De 
uitgevoerde meta-analyse bevat data van 11 cohort studies (in totaal 65019 deelnemers) en 
laat zien dat verhoogde basale cardiale troponineconcentraties samenhangen met een 
grotere de kans op vroegtijdig overlijden.  
Tot slot bevat hoofdstuk 12 een algemene discussie over het in dit proefschrift beschreven 
werk en worden suggesties voor vervolgonderzoek aangedragen.  
Valorization
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This chapter describes the (future) valorization of the research described in this thesis. 
Valorization is thereby defined as the social and economic relevance of research, the target 
populations of the findings, the related concrete products, services, processes and activities, 
their innovativeness and future directions1.   
 
Relevance  
According to the World Health Organization (WHO), cardiovascular disease, of which acute 
myocardial infarction is considered as an important entity2, is the world’s number one killer, 
responsible for approximately 31% of all deaths worldwide3. Along, cardiovascular disease 
substantially contributes to disability and decreased quality of life4,5. A recent economic 
evaluation showed that cardiovascular disease accounts for approximately 12% of the total 
European health care expenditures6,7. However, this may be even an underestimation since 
the total economic impact on society is bigger due to productivity losses and informal care 
as result of chronic disease and disability7. Urbanization and associated changes in lifestyle 
at one hand, and longevity at the other hand, will further increase the prevalence of 
cardiovascular disease in the coming years8,9.  
This thesis focuses on two ways in which the accurate interpretation of cardiac troponin 
concentrations may contribute to lower the burden of cardiovascular disease: The distinction 
of patients with and without myocardial infarction in the acute setting, and the identification 
of subjects at increased risk for future events based on basal cardiac troponin 
concentrations.  
 
Target population 
Since this thesis focuses on the optimization of interpretation of cardiac troponin 
concentrations in both the acute (diagnostic) and chronic (prognostic) setting, its findings are 
relevant for a large population. For example, whereas the novel insights on combining 
cardiac troponin T and cardiac troponin I for the early rule-out of acute myocardial infarction 
refer to emergency department patients, the results on the prognostic value of cardiac 
troponins are applicable to the general population. 
Valorization 
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Products 
As already described in the discussion chapter of this thesis, many of our findings trigger 
further research. An example of a concept that requires additional research is the application 
of cardiac troponins for prognosis and prevention. In contrast, a more concrete and 
innovative concept is the combination of cardiac troponin T and cardiac troponin I for the 
diagnosis of acute myocardial infarction.  
 
Implementation of combination testing in clinical practice  
We showed that combining cardiac troponin T and cardiac troponin I in de diagnostic setting 
is highly promising to overcome the limited specificity of the separate assays. It results in a 
significant increase in patients in which acute myocardial infarction could be safely ruled-out 
at presentation (from approximately 10% to more than 40%). Therefore, the implementation 
of this combination strategy may have profound consequences for clinical practice since it 
may help to overcome unnecessary resource use, overcrowding of the emergency 
department and anxiety among patients10. The fact that high-sensitivity cardiac troponin T 
and high-sensitivity cardiac troponin I assays do currently not run on the same platform and 
most laboratories have only one platform running 24/7 for routine measurements is an 
important obstacle for the introduction of this strategy in clinical practice. The development 
of (point of care) devices suitable for combined measurement – a project involving diagnostic 
companies, laboratories and physicians – is therefore crucial. Parallel, we should evaluate 
the optimal place of combination testing in the diagnostic chain – directly at presentation in 
the hospital or maybe even earlier at the general practice or in the ambulance setting – , and 
define optimal algorithms with optimal cut-off values, taking into account the effects of 
combination testing and the increased number of rule-outs at presentation downstream the 
diagnostic chain.  
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